BRPI0513089B8 - forma de dosagem para liberação controlada de um fármaco de ordem ascendente de zero - Google Patents
forma de dosagem para liberação controlada de um fármaco de ordem ascendente de zeroInfo
- Publication number
- BRPI0513089B8 BRPI0513089B8 BRPI0513089A BRPI0513089A BRPI0513089B8 BR PI0513089 B8 BRPI0513089 B8 BR PI0513089B8 BR PI0513089 A BRPI0513089 A BR PI0513089A BR PI0513089 A BRPI0513089 A BR PI0513089A BR PI0513089 B8 BRPI0513089 B8 BR PI0513089B8
- Authority
- BR
- Brazil
- Prior art keywords
- drug
- ascending order
- zero
- controlled release
- dosage form
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 5
- 229940079593 drug Drugs 0.000 title abstract 5
- 230000001174 ascending effect Effects 0.000 title abstract 2
- 238000013270 controlled release Methods 0.000 title abstract 2
- 239000002552 dosage form Substances 0.000 title abstract 2
- 239000011159 matrix material Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 238000013267 controlled drug release Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Psychology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Laminated Bodies (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US59912604P | 2004-08-04 | 2004-08-04 | |
PCT/US2005/027490 WO2006017537A1 (en) | 2004-08-04 | 2005-08-02 | Sustained drug release composition demonstrating an ascending zero order release pattern, methods of manufacturing such a composition |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0513089A BRPI0513089A (pt) | 2008-04-29 |
BRPI0513089B1 BRPI0513089B1 (pt) | 2019-10-29 |
BRPI0513089B8 true BRPI0513089B8 (pt) | 2021-05-25 |
Family
ID=35229686
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0513089A BRPI0513089B8 (pt) | 2004-08-04 | 2005-08-02 | forma de dosagem para liberação controlada de um fármaco de ordem ascendente de zero |
Country Status (16)
Country | Link |
---|---|
US (1) | US20060034927A1 (pt) |
EP (1) | EP1802286B1 (pt) |
JP (1) | JP2008509144A (pt) |
KR (1) | KR101340946B1 (pt) |
CN (1) | CN101035519A (pt) |
AT (1) | ATE401868T1 (pt) |
AU (1) | AU2005271522B2 (pt) |
BR (1) | BRPI0513089B8 (pt) |
CA (1) | CA2575484A1 (pt) |
DE (1) | DE602005008460D1 (pt) |
IL (1) | IL181117A (pt) |
MX (1) | MX2007001563A (pt) |
NO (1) | NO338672B1 (pt) |
NZ (1) | NZ552841A (pt) |
WO (1) | WO2006017537A1 (pt) |
ZA (1) | ZA200701878B (pt) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080292700A1 (en) * | 1997-04-21 | 2008-11-27 | Biovail Laboratories | Controlled release formulations using intelligent polymers |
US20050232995A1 (en) * | 2002-07-29 | 2005-10-20 | Yam Nyomi V | Methods and dosage forms for controlled delivery of paliperidone and risperidone |
US20050208132A1 (en) * | 2002-07-29 | 2005-09-22 | Gayatri Sathyan | Methods and dosage forms for reducing side effects of benzisozazole derivatives |
US9744137B2 (en) * | 2006-08-31 | 2017-08-29 | Supernus Pharmaceuticals, Inc. | Topiramate compositions and methods of enhancing its bioavailability |
CA2662265A1 (en) * | 2006-09-01 | 2008-03-06 | Teva Pharmaceutical Industries Ltd. | Imatinib compositions |
EP2394643B1 (en) | 2006-11-17 | 2015-09-02 | Supernus Pharmaceuticals, Inc. | Sustained-release formulations of topiramate |
CN102114002B (zh) * | 2006-12-04 | 2016-05-11 | 苏佩努斯制药公司 | 托吡酯的增强的立即释放制剂 |
WO2009025859A1 (en) * | 2007-08-21 | 2009-02-26 | Teva Pharmaceutical Industries Ltd. | Paliperidone sustained release formulation |
US20090060983A1 (en) * | 2007-08-30 | 2009-03-05 | Bunick Frank J | Method And Composition For Making An Orally Disintegrating Dosage Form |
BRPI0817946A2 (pt) * | 2007-09-25 | 2015-05-05 | Teva Pharma | Composições de imatinibe estável |
AU2008318851B2 (en) * | 2007-10-31 | 2014-04-17 | Mcneil-Ppc, Inc. | Orally disintegrated dosage form |
BRPI0906754A2 (pt) * | 2008-02-04 | 2015-07-07 | Torrent Pharmaceuticals Ltd | Formulário de dosage prolongado da libertação de paliperidone |
WO2010009900A1 (en) * | 2008-07-25 | 2010-01-28 | Krka, D.D. Novo Mesto | Paliperidone composition comprising solid matrix particles |
EP2161019A1 (en) * | 2008-09-05 | 2010-03-10 | KRKA, D.D., Novo Mesto | Prolonged release multiparticulate pharmaceutical composition comprising paliperidone |
WO2010044097A2 (en) | 2008-09-15 | 2010-04-22 | Intas Pharmaceuticals Limited | Novel dosage form of paliperidone and process for preparing the same |
WO2010089775A2 (en) * | 2009-02-05 | 2010-08-12 | Getz Pharma Research | Improved drug dosage form for controlled delivery of one or more pharmaceutically active agent |
WO2011018246A2 (en) | 2009-08-13 | 2011-02-17 | Synthon B.V. | Controlled release paliperidone composition |
US20110052687A1 (en) * | 2009-08-26 | 2011-03-03 | Glenmark Generics Ltd | Extended release pharmaceutical composition of paliperidone |
US20110070301A1 (en) | 2009-09-24 | 2011-03-24 | Luber Joseph R | Orally transformable tablets |
US20110318411A1 (en) | 2010-06-24 | 2011-12-29 | Luber Joseph R | Multi-layered orally disintegrating tablet and the manufacture thereof |
US8313768B2 (en) * | 2009-09-24 | 2012-11-20 | Mcneil-Ppc, Inc. | Manufacture of tablet having immediate release region and sustained release region |
US20110070286A1 (en) * | 2009-09-24 | 2011-03-24 | Andreas Hugerth | Process for the manufacture of nicotine-comprising chewing gum and nicotine-comprising chewing gum manufactured according to said process |
US8758780B2 (en) | 2009-10-06 | 2014-06-24 | Ascendis Pharma As | Subcutaneous paliperidone composition |
WO2011042450A1 (en) | 2009-10-06 | 2011-04-14 | Ascendis Pharma As | Carrier linked paliperidone prodrugs |
US9271939B2 (en) | 2010-03-15 | 2016-03-01 | Inventia Healthcare Private Limited | Stabilized prolonged release pharmaceutical composition comprising atypical antipsychotic |
US20120201886A1 (en) | 2010-07-30 | 2012-08-09 | Micro Labs Limited | Coated Extended Release Pharmaceutical Compositions Containing Paliperidone |
CN102058517A (zh) * | 2010-12-31 | 2011-05-18 | 泰州万全医药科技有限公司 | 一种帕潘立酮缓释剂及其制备方法 |
LT2529756T (lt) | 2011-05-31 | 2021-07-26 | Laboratorios Farmaceuticos Rovi, S.A. | Risperidono ir (arba) paliperidono implantų kompozicija |
ES2456917T3 (es) | 2011-05-31 | 2014-04-24 | Laboratorios Farmacéuticos Rovi, S.A. | Formulación de implante de paliperidona |
US20130034605A1 (en) | 2011-08-01 | 2013-02-07 | Micro Labs Limited | Extended release pharmaceutical compositions containing paliperidone |
CN102579367B (zh) * | 2012-03-23 | 2014-03-12 | 中国人民解放军军事医学科学院毒物药物研究所 | 托吡酯缓释药物组合物、其制备方法及用途 |
EP2829270B1 (en) | 2012-03-23 | 2020-11-11 | Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China | Joint product containing synephrine and topiramate |
CN103316026B (zh) | 2012-03-23 | 2016-05-11 | 中国人民解放军军事医学科学院毒物药物研究所 | 含芬特明和托吡酯的联合产品及其制备方法 |
US9233491B2 (en) | 2012-05-01 | 2016-01-12 | Johnson & Johnson Consumer Inc. | Machine for production of solid dosage forms |
US9445971B2 (en) | 2012-05-01 | 2016-09-20 | Johnson & Johnson Consumer Inc. | Method of manufacturing solid dosage form |
US9511028B2 (en) | 2012-05-01 | 2016-12-06 | Johnson & Johnson Consumer Inc. | Orally disintegrating tablet |
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
WO2014167439A1 (en) * | 2013-03-26 | 2014-10-16 | Wockhardt Limited | Modified release pharmaceutical compositions of topiramate or salts thereof |
CN103271889B (zh) * | 2013-05-23 | 2015-10-28 | 沈阳药科大学 | 帕利哌酮新型递增释放渗透泵制剂及其制备方法 |
EP3091966B1 (en) | 2014-01-10 | 2019-07-31 | Johnson & Johnson Consumer Inc. | Process for making tablet using radiofrequency and lossy coated particles |
JP7083312B2 (ja) * | 2016-04-26 | 2022-06-10 | エルテーエス ローマン テラピー-ジステーメ アーゲー | 抗糖尿病ペプチドの経粘膜送達用のフィルム状投与形態 |
US10493026B2 (en) | 2017-03-20 | 2019-12-03 | Johnson & Johnson Consumer Inc. | Process for making tablet using radiofrequency and lossy coated particles |
GB201715109D0 (en) * | 2017-09-19 | 2017-11-01 | Johnson Matthey Plc | Release system and method |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2236483B1 (pt) * | 1973-07-12 | 1976-11-12 | Choay Sa | |
US4316884A (en) * | 1979-01-25 | 1982-02-23 | Adria Laboratories, Inc. | Sustained release pharmaceutical formulation |
DE3045135A1 (de) * | 1980-11-29 | 1982-06-09 | Sandoz-Patent-GmbH, 7850 Lörrach | Pharmazeutische kompositionen enthaltende bioabbaubare polymere |
DE3508097A1 (de) * | 1984-07-21 | 1986-02-06 | Hoechst Ag, 6230 Frankfurt | Kombinationspraeparat aus xanthinderivaten und o-acetylsalicylsaeure bzw. deren pharmakologisch vertraeglichen salzen und dessen verwendung |
EP0230654B1 (en) * | 1985-12-28 | 1992-03-18 | Sumitomo Pharmaceuticals Company, Limited | Sustained pulsewise release pharmaceutical preparation |
CA2050911C (en) * | 1989-05-04 | 1997-07-15 | Thomas R. Tice | Encapsulation process and products therefrom |
KR930006431B1 (ko) * | 1990-10-11 | 1993-07-16 | 재단법인 한국화학연구소 | 약물의 미세캡슐화 방법 |
IT1256393B (it) * | 1992-11-17 | 1995-12-04 | Inverni Della Beffa Spa | Forme matriciali multistrato per il rilascio controllato di principi attivi |
US5407687A (en) * | 1994-02-22 | 1995-04-18 | Glaxo Inc. | Ranitidine solid dosage form |
US5582838A (en) * | 1994-12-22 | 1996-12-10 | Merck & Co., Inc. | Controlled release drug suspension delivery device |
CA2264852C (en) * | 1996-09-30 | 2005-11-01 | Alza Corporation | Use of methylphenidate or a pharmaceutically acceptable salt thereof |
US6919373B1 (en) * | 1996-11-12 | 2005-07-19 | Alza Corporation | Methods and devices for providing prolonged drug therapy |
EP2277517A1 (en) * | 1996-11-15 | 2011-01-26 | Ajinomoto Co., Inc. | Nateglinide tablet composition |
US5980942A (en) * | 1997-01-23 | 1999-11-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Zero-order sustained release matrix tablet formulations of carbamazepine |
PL356300A1 (en) * | 1999-12-28 | 2004-06-28 | Ajinomoto Co, Inc. | Oral preparations for diabetes |
GB0117618D0 (en) * | 2001-07-19 | 2001-09-12 | Phoqus Ltd | Pharmaceutical dosage form |
JP4500679B2 (ja) * | 2002-07-29 | 2010-07-14 | アルザ・コーポレーシヨン | パリペリドンを制御送達する方法および投薬形態物 |
-
2005
- 2005-08-02 NZ NZ552841A patent/NZ552841A/en not_active IP Right Cessation
- 2005-08-02 CN CNA2005800335945A patent/CN101035519A/zh active Pending
- 2005-08-02 DE DE602005008460T patent/DE602005008460D1/de active Active
- 2005-08-02 EP EP05779051A patent/EP1802286B1/en not_active Not-in-force
- 2005-08-02 JP JP2007524929A patent/JP2008509144A/ja active Pending
- 2005-08-02 US US11/196,556 patent/US20060034927A1/en not_active Abandoned
- 2005-08-02 AU AU2005271522A patent/AU2005271522B2/en not_active Ceased
- 2005-08-02 AT AT05779051T patent/ATE401868T1/de not_active IP Right Cessation
- 2005-08-02 BR BRPI0513089A patent/BRPI0513089B8/pt not_active IP Right Cessation
- 2005-08-02 CA CA002575484A patent/CA2575484A1/en not_active Abandoned
- 2005-08-02 WO PCT/US2005/027490 patent/WO2006017537A1/en active Application Filing
- 2005-08-02 KR KR1020077004326A patent/KR101340946B1/ko active IP Right Grant
- 2005-08-02 MX MX2007001563A patent/MX2007001563A/es active IP Right Grant
-
2007
- 2007-02-01 IL IL181117A patent/IL181117A/en not_active IP Right Cessation
- 2007-03-01 NO NO20071175A patent/NO338672B1/no not_active IP Right Cessation
- 2007-03-02 ZA ZA200701878A patent/ZA200701878B/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2005271522B2 (en) | 2011-02-10 |
CN101035519A (zh) | 2007-09-12 |
IL181117A0 (en) | 2007-07-04 |
EP1802286B1 (en) | 2008-07-23 |
US20060034927A1 (en) | 2006-02-16 |
ZA200701878B (en) | 2008-07-30 |
ATE401868T1 (de) | 2008-08-15 |
DE602005008460D1 (de) | 2008-09-04 |
CA2575484A1 (en) | 2006-02-16 |
MX2007001563A (es) | 2008-03-05 |
IL181117A (en) | 2010-11-30 |
NO338672B1 (no) | 2016-09-26 |
NZ552841A (en) | 2009-07-31 |
KR101340946B1 (ko) | 2013-12-13 |
WO2006017537A1 (en) | 2006-02-16 |
EP1802286A1 (en) | 2007-07-04 |
BRPI0513089B1 (pt) | 2019-10-29 |
NO20071175L (no) | 2007-05-03 |
BRPI0513089A (pt) | 2008-04-29 |
AU2005271522A1 (en) | 2006-02-16 |
KR20070069136A (ko) | 2007-07-02 |
JP2008509144A (ja) | 2008-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0513089B8 (pt) | forma de dosagem para liberação controlada de um fármaco de ordem ascendente de zero | |
CR8858A (es) | Derivados de sulfamato y sulfamida para el tratamiento de epilepsia y trastornos relacionados | |
BRPI0812418B8 (pt) | artigo absorvente descartável com material polimérico absorvente distribuído de modo substancialmente contínuo e método | |
GT200600194A (es) | Composiciones farmaceuticas conteniendo imatinib y un componente de liberacion prolongada | |
CL2007003355A1 (es) | Suela transpirante e impermeable para calzados, con una cara de desgaste que presenta una pluralidad de orificios pasantes, que tiene un elemento en forma de capa transpirante y una capa protectora; calzado; y procedimiento para realizar una suela. | |
BRPI0513847A (pt) | formulação de comprimido de liberação extendida contendo pramipexol ou um sal farmaceuticamente aceitável do mesmo, método para a fabricação do mesmo e uso do mesmo | |
BRPI0318456B8 (pt) | tablete com liberação modificada | |
CL2007003797A1 (es) | Compuestos derivados de pirrolo piridina; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la enfermedad de alzheimer, parkinson, cancer, entre otras enfermedades. | |
CL2007002121A1 (es) | Compuestos derivados de pirazoles, activadores de glucoquinasa; proceso de preparacion de dichos compuestos; composicion farmaceutica que comprende dichos compuestos; y uso para el tratamiento de enfermedades y/o trastornos metabolicos, tal como diab | |
ECSP099320A (es) | Compuestos de tetrahidropirrolopiracina sustituida y su aplicación en medicamentos | |
CL2007002572A1 (es) | Compuestos derivados de benzotiazol, moduladores de quinasa; composicion farmaceutica que los contiene; y su uso para el tratamiento de un trastorno mediado por la quinasa c-jun-n-terminal, tales como trastornos autoinmunes, inflamatorios, metabolico | |
ECSP088875A (es) | Tienopirimidinas con actividad inhibidora de mnk1/mnk2 para composiciones farmacéuticas | |
WO2007136656A3 (en) | Colored masking for forming transparent structures | |
CL2007001325A1 (es) | Compuestos derivados de biciclos, inhibidores de cept; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar hiperlipidemia, arterioesclerosis, entre otras enfermedades. | |
BRPI0515940A (pt) | membro linear | |
CL2008000691A1 (es) | Compuestos derivados de dihidro y tetrahidro oxazolopirimidinonas sustituidas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la esquizofrenia, epilepsia, entre otras enfermedades. | |
PA8770101A1 (es) | Amidas de 4-aril-1,4-dihidro-1, 6-naftiridina sustituidas y su uso | |
BR112013024585A8 (pt) | formas de dosagem farmacêutica de liberação controlada | |
BRPI0501449A (pt) | Mistura funcional, processos para curar e para curar parcialmente uma mistura funcional, e, adesivo | |
UY31530A (es) | "poliaminas reticuladas y sus usos en composiciones farmacéuticas" | |
BRPI0513702A (pt) | comprimidos revestidos gelatinosos que se desintegram rapidamente | |
CL2007003423A1 (es) | Compuestos derivados de pirimidinas sustituidas; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de artritis reumatoidea, aterosclerosis, entre otras enfermeda | |
CL2007002971A1 (es) | Compuestos derivados de aminometil-4-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y su uso para tratar depresion, ansiedad, trastorno bipolar, entre otras. | |
CL2007002371A1 (es) | Metodo para administrar un agente terapeutico que comprende administrar una composicion de nanoparticulas que comprende una matriz polimerica junto con un cation divalente que contiene un agente terapeutico; y dicha composicion. | |
CL2007003855A1 (es) | Composicion que comprende un vehiculo sustrato y un deposito sobre dicho vehiculo sustrato, donde dicho deposito comprende particulas de un compuesto derivado de pregnano; capsula y tableta que la comprenden; y uso en el tratamiento de enfermedades t |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/10/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/10/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/08/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 17A ANUIDADE. |
|
B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2681 DE 24-05-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |